Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Study Type
EXPANDED_ACCESS
patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks
Kangnam St. Mary's Hospital
Seoul, South Korea
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.